UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549-1004
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): April 12, 2006
Ciphergen Biosystems, Inc.
(Exact name of Registrant as specified in its charter)
|
Delaware |
|
000-31617 |
|
33-059-5156 |
|
(State or other jurisdiction of |
|
[Commission File Number] |
|
(I.R.S. Employer |
|
|
|
|
|
|
|
6611 Dumbarton Circle |
||||
|
(Address of principal executive offices) |
||||
|
|
|
|
|
|
|
(510) 505-2100 |
||||
|
(Registrant’s telephone number, including area code) |
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On April 12, 2005, Kenneth J. Conway was appointed to the Ciphergen Biosystems, Inc. (the “Company”) Board of Directors (the “Board”) as a new ninth member of the Board. Mr. Conway will serve as a Class I director on the Board. It has not been determined which, if any, committees of the Board Mr. Conway will serve on.
The Company is issuing a press release regarding the appointment of Mr. Conway to the Board, a copy of which is furnished as Exhibit 99.1 to this Form 8-K. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release of Ciphergen Biosystems, Inc. dated as of April 18, 2006. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CIPHERGEN BIOSYSTEMS, INC. |
||
|
|
(Registrant) |
||
|
|
|
|
|
|
Date: April 18, 2006 |
By: |
/S/ GAIL S. PAGE |
|
|
|
Gail S. Page |
||
|
|
President and Chief Executive Officer |
||
3
Exhibit Index
|
Exhibit |
|
Exhibit Title |
|
|
|
|
|
99.1 |
|
Press Release of Ciphergen Biosystems, Inc. dated as of April 18, 2006. |
4